For roughly 64 million people living with heart failure worldwide, the most dangerous moment is rarely the diagnosis. It is the slow, silent slide into decompensation: fluid building in the lungs over days or weeks, breath shortening, until an emergency department becomes the only option. A Berlin startup is betting that the earliest signal of that slide is hiding in something patients already do every day, which is talk.
Noah Labs, founded in 2021, has built an algorithm called Vox that listens to short voice recordings from patients with chronic heart failure and flags signs of pulmonary congestion before symptoms force a hospital visit. In March 2026, the US Food and Drug Administration granted Vox a Breakthrough Device Designation, a status reserved for technologies that may offer more effective treatment or diagnosis of life-threatening conditions [Noah Labs, March 2026]. The designation does not equal clearance, but it puts Vox on a faster review track and signals that the agency considers the underlying clinical question serious.
The bet
Noah Labs sells into hospitals and health systems through two products. Ark is a Class IIa Medical Device Software under the EU Medical Device Regulation, designed for remote monitoring of chronic cardiovascular conditions including heart failure, hypertension, and arrhythmia, and it pulls real-time vital data from approved devices and implants [Noah Labs, retrieved 2026]. Vox is the voice layer that sits inside Ark, using deep learning models trained on proprietary audio datasets to detect impending decompensation [Noah Labs, retrieved 2026]. The commercial wedge is a B2B software contract with cardiology departments and telemonitoring services, with the clinical pitch that earlier intervention reduces the costly, traumatic hospitalizations that drive most of the spend in heart failure care.
Today's standard of care for chronic heart failure patients in Europe and the US is a combination of guideline-directed medical therapy (typically the four pillars: ARNI or ACE inhibitor, beta-blocker, MRA, and SGLT2 inhibitor), periodic clinic visits, and self-reported symptom tracking such as daily weights. More advanced telemonitoring exists, including implantable pulmonary artery pressure sensors like Abbott's CardioMEMS, but those are invasive and reserved for selected NYHA Class III patients. Most patients still rely on the gap between scheduled appointments, which is precisely the window in which decompensation tends to occur. A non-invasive voice biomarker, if validated, would slot into a real clinical hole.
Why it could matter
The regulatory and partnership signals around Noah Labs are unusually concrete for a seed-stage company. Beyond the FDA Breakthrough tag, the company holds ISO 13485 certification as a medical device manufacturer and has secured Class IIa approval for Ark [Noah Labs, retrieved 2026]. Vox is being evaluated in the PRE-DETECT-HF clinical trial at Clinic Barcelona and University Medical Center Maastricht, and the company reports the algorithm has been studied across five multicentre trials with partners including Mayo Clinic and the University of California San Francisco [Medical Device Network, retrieved 2026]. Noah Labs was also the first startup admitted to Herz-Hirn-Allianz, a Novartis-led coalition targeting a 30 percent reduction in cardiovascular events by 2030 [Noah Labs, retrieved 2026].
The cap table reflects that traction. Nina Capital, a healthcare-focused European fund, led a roughly $3.3 million seed in September 2024, building on an earlier angel round of around $988,000 in November 2022 [Vestbee, Sep 2024] [Crunchbase, Nov 2022]. Investors include ILB, adesso ventures, and the DHZB Foundation, the philanthropic arm associated with the German Heart Center. Non-dilutive support has done much of the heavy lifting since: the company has been selected for the EIC Accelerator and Berlin Startup Stipend programs, and disclosed grants tied to the EU and EIT Health.
Angel 2022 | 0.99 | $M
Seed 2024 (Nina Capital) | 3.30 | $M
ILB ProFIT grant | 3.30 | $M
EIT Health grant | 1.65 | $M
EU grant | 11.90 | $M
The team
Noah Labs was founded by Oliver Weiss Piepenstock, who serves as CEO, alongside co-founders Marcus Hott and Dr. Leonhard Riehle [Noah Labs, retrieved 2026]. Piepenstock trained as a financial economist at Copenhagen Business School and worked in investment banking before founding Mecasa, a care platform, ahead of Noah Labs [ahahealthtech.org, retrieved 2026]. Hott, the CTO, previously worked as an AI programmer at Harvard Medical School, where the team's interest in machine learning applied to cardiovascular signals took root [Noah Labs, retrieved 2026]. The combination, a healthcare operator with a prior company under his belt and a technical co-founder with academic ML chops, is well matched to a regulated software-as-a-medical-device path.
What bears say, what bulls answer
The most credible concern is data generalization. Vox's deep learning models are trained on proprietary audio datasets [Noah Labs, retrieved 2026], and voice biomarkers are notoriously sensitive to language, accent, recording hardware, and background noise. A model that performs in a controlled cohort can degrade on a different population. The company's response, as reflected in its trial program, is to validate across multiple sites and geographies before broad commercial launch: the PRE-DETECT-HF arms in Barcelona and Maastricht test the algorithm against Catalan, Spanish, and Dutch-speaking patients, and the cited collaborations with Mayo Clinic and UCSF extend that to US English populations [Medical Device Network, retrieved 2026]. Whether the published readouts confirm meaningful sensitivity and specificity is the question that will decide the company's commercial trajectory.
What to watch
The next twelve months are clinically and regulatorily dense. The PRE-DETECT-HF readouts will be the most consequential data point, and any peer-reviewed publication of the multicentre validation work will materially change how cardiologists weigh the technology. On the regulatory side, the FDA Breakthrough Device Designation sets up a US clearance pathway that, if pursued aggressively, could put Vox in front of American heart failure programs alongside its European footprint. A Series A would be the natural financing step to fund commercial buildout once a clearance timeline firms up, and the existing Nina Capital and adesso ventures relationships make a healthcare-led round the likeliest shape. For now, the patient population this matters most to, adults with NYHA Class II to IV heart failure managing the disease at home, has a reason to pay attention to a startup arguing that the next clinical signal might come through the phone rather than the clinic door.
Pulse Raman, Health and Bio Correspondent